FIELD: medicine.
SUBSTANCE: present invention relates to compounds that modulate a function of an orphan receptor RORc (RORy) related to retinoid receptors, namely to specific compounds as they are presented in the claims. A pharmaceutical composition and the use of compounds for the preparation of a drug and the treatment or prevention of a disease mediated by the RORc receptor are also proposed.
EFFECT: obtaining new organic compounds that modulate the function of the orphan receptor RORc related to retinoid receptors and that can be used for the treatment of autoimmune diseases.
10 cl, 2 tbl, 88 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIDAZINE DERIVATIVES | 2006 |
|
RU2401832C2 |
| ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1(11β-HSD 1) | 2007 |
|
RU2417989C2 |
| BORONIC ACID DERIVATIVES | 2018 |
|
RU2793315C2 |
| MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
| TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
| NEW LIGANDS OF CANNACBINOID RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHOD FOR PRODUCING THEREOF | 2006 |
|
RU2420518C2 |
| PIPERIDINE DERIVATIVES | 2011 |
|
RU2554353C2 |
| MTOR KINASE INHIBITORS FOR ONCOLOGIC INDICATIONS AND DISEASES ASSOCIATED WITH MTOR/PI3K/AKT BY METABOLISM | 2009 |
|
RU2692796C2 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
